Litak

cladribine · Lipomed GmbH
AUTHORISED IN THE EU

What Litak is used for

Litak is indicated for the treatment of hairy-cell leukaemia.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Litak
Active substance
cladribine
Disease area
Leukemia, Hairy Cell
Medicine group
Antineoplastic agents
ATC code
L01BB04
Marketing authorisation holder
Lipomed GmbH
Authorised in the EU since
2004

Official information

In the USA

Same active substance: Mavenclad

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Litak used for?

Litak is indicated for the treatment of hairy-cell leukaemia.

What is the active substance in Litak?

Litak contains cladribine.

Who makes Litak?

The EU marketing authorisation holder is Lipomed GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.